Cargando…

“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management

BACKGROUND: We explored health professionals’ views on the utility of circulating tumor DNA (ctDNA) testing in hereditary cancer syndrome (HCS) management. MATERIALS AND METHODS: A qualitative interpretive description study was conducted, using semi-structured interviews with professionals across Ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shickh, Salma, Oldfield, Leslie E, Clausen, Marc, Mighton, Chloe, Sebastian, Agnes, Calvo, Alessia, Baxter, Nancy N, Dawson, Lesa, Penney, Lynette S, Foulkes, William, Basik, Mark, Sun, Sophie, Schrader, Kasmintan A, Regier, Dean A, Karsan, Aly, Pollett, Aaron, Pugh, Trevor J, Kim, Raymond H, Bombard, Yvonne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Health Outcomes and Economics of Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075003/ https://www.ncbi.nlm.nih.gov/pubmed/35385106 http://dx.doi.org/10.1093/oncolo/oyac039

Ejemplares similares

Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy
por: Farncombe, Kirsten M., et al.
Publicado: (2023)

From the patient to the population: Use of genomics for population screening
por: Mighton, Chloe, et al.
Publicado: (2022)

Quality of life drives patients’ preferences for secondary findings from genomic sequencing
por: Mighton, Chloe, et al.
Publicado: (2020)

Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System
por: Richardson, Matthew, et al.
Publicado: (2020)

Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication
por: Pollard, Samantha, et al.
Publicado: (2020)

Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery
por: Shickh, Salma, et al.
Publicado: (2022)

Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial
por: Shickh, Salma, et al.
Publicado: (2018)

Development and early‐stage evaluation of a patient portal to enhance familial communication about hereditary cancer susceptibility testing: A patient‐driven approach
por: Pollard, Samantha, et al.
Publicado: (2023)

CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome
por: Cremin, Carol, et al.
Publicado: (2018)

Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
por: Kwon, Janice S., et al.
Publicado: (2022)

The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers
por: Weymann, Deirdre, et al.
Publicado: (2017)

Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial
por: Shickh, Salma, et al.
Publicado: (2019)

Heath policy guiding the identification, analysis and management of secondary findings for individuals undergoing genomic sequencing: a systematic review protocol
por: Majeed, Safa, et al.
Publicado: (2022)

Quality-of-Life Outcomes With Minimally Invasive Transforaminal Lumbar Interbody Fusion Based on Long-Term Analysis of 304 Consecutive Patients
por: Perez-Cruet, Mick J., et al.
Publicado: (2014)

Treatment Outcome of Metastatic Spine Tumor in Lung Cancer Patients: Did the Treatments Improve Their Outcomes?
por: Uei, Hiroshi, et al.
Publicado: (2017)

Prognostic predictors of early mortality from exsanguination in adult trauma: a Malaysian trauma center experience
por: Huei, Tan Jih, et al.
Publicado: (2017)

What is the patient experience of surgical care during the coronavirus disease 2019 (COVID-19) pandemic? A mixed-methods study at a single institution
por: Shannon, Adrienne B., et al.
Publicado: (2021)

Reduced duration of stay after elective colorectal surgery during the peak phase of COVID-19 pandemic: A positive effect of infection risk awareness?
por: Spinelli, Antonino, et al.
Publicado: (2021)

Longitudinal electrocardiographic assessment in Brugada syndrome
por: Daw, Jonathan M., et al.
Publicado: (2022)

Measuring cataract outcomes
por: Buchan, John
Publicado: (2022)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2015)

Game Changers
Publicado: (2015)

Game changers
Publicado: (2016)

Severity of nausea and vomiting in pregnancy and early childhood neurobehavioural outcomes: The Growing Up in Singapore Towards Healthy Outcomes study
por: Syn, Nicholas L., et al.
Publicado: (2020)

Hereditary diffuse gastric cancer: association with lobular breast cancer
por: Schrader, Kasmintan A., et al.
Publicado: (2007)

Effect of Blood Pressure Variability on Outcomes in Emergency Patients with Intracranial Hemorrhage
por: Tran, Quincy K., et al.
Publicado: (2021)

Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006–2016
por: Adolph, Lauren, et al.
Publicado: (2022)

Outcomes before and after providing interdisciplinary hematology and pulmonary care for children with sickle cell disease
por: Zeno, Rachel N., et al.
Publicado: (2022)

SDF − a game changer?
por: Remtulla, A.
Publicado: (2020)

Clinical and cost outcomes following genomics‐informed treatment for advanced cancers
por: Weymann, Deirdre, et al.
Publicado: (2021)

Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing
por: Thibodeau, My Linh, et al.
Publicado: (2020)

Digital health: a game changer
Publicado: (2019)

Intelligentes Wissensmanagement als Game Changer
por: Fallmann, Daniel
Publicado: (2021)

Das Virus als Game Changer
por: Vollrath, Fabian
Publicado: (2021)

Assessment of SLX4 Mutations in Hereditary Breast Cancers
por: Shah, Sohela, et al.
Publicado: (2013)

Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention
por: Tindale, Lauren C., et al.
Publicado: (2022)

Dexmedetomidine: The game changer or a team player?
por: Goyal, Rakhee
Publicado: (2016)

Reflecting on ICN2: was it a game changer?
por: Brinsden, Hannah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eovlplon5qtuq62olnkquhgoh9